Hemodynamic Effect of Lumbosacral Plexus Blockade Versus Spinal Anesthesia
Surgical Anesthesia for Elective Hip Surgery - Hemodynamic Effect of Lumbosacral Plexus Blockade Compared to Spinal Anesthesia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Silkeborg, Denmark, 8600
- Center for Planlagt Kirurgi
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients for total hip replacement at Aarhus University Hospital
- Age >= 50 years
- American Society of Anesthesiologists physical status classification score I-III
- Informed consent
Exclusion Criteria:
- Lack of ability to cooperate
- Lack of ability to speak Danish
- Chronic pain, that demands opioid treatment. Not inkl. hip pain.
- Previous venous thromboembolic event
- Previous major back surgery
- Severe cardiopulmonary disease (NYHA class 4)
- Severe untreated hypertension (systolic blood pressure > 160 mm Hg or diastolic blood pressure > 110 mm Hg)
- Obesity (BMI > 35 kg/m^2)
- Pregnancy
- Allergy towards the used local analgetics
- Current treatment with amiodarone or verapamil
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Lumbosacral plexus blockade
Peripheral nerve blockade of lumbar and sacral plexus with ropivacaine max 225 mg perineural
|
Lumbosacral plexus blockade with ropivacaine.
|
|
ACTIVE_COMPARATOR: Continuous spinal anesthesia
Continuous spinal anesthesia with plain bupivacaine max 15 mg intrathecal
|
Regional anesthesia with bupivacaine titrated to the lowest effective dose
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of cardiac output
Time Frame: Up to 1 hour
|
Change from baseline (before nerve block performance) to 30 minutes after 1st dose of intrathecal study medicine.
|
Up to 1 hour
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time for performance of nerve blocks
Time Frame: At time of nerve block performance
|
Time range (in minutes) from first insertion to last withdrawal of nerve block needle.
|
At time of nerve block performance
|
|
Success rate of nerve blocks
Time Frame: 1 day
|
1 day
|
|
|
Change of cardiac stroke volume
Time Frame: Up to 1 hour
|
Change from baseline (before nerve block performance) to 30 minutes after 1st dose of intrathecal study medicine.
|
Up to 1 hour
|
|
Change of systemic vascular resistance
Time Frame: Up to 1 hour
|
Change from baseline (before nerve block performance) to 30 minutes after 1st dose of intrathecal study medicine.
|
Up to 1 hour
|
|
Change of mean arterial pressure
Time Frame: Up to 1 hour
|
Change from baseline (before nerve block performance) to 30 minutes after 1st dose of intrathecal study medicine.
|
Up to 1 hour
|
|
Change of central venous oxygen saturation
Time Frame: Up to 1 hour
|
Change from baseline (before nerve block performance) to 30 minutes after 1st dose of intrathecal study medicine.
|
Up to 1 hour
|
|
Maximum plasma concentration of ropivacaine
Time Frame: 80 minutes
|
Arterial blood sampling at 20, 40, 60 and 80 minutes after 1st dose of intrathecal study medicine.
|
80 minutes
|
|
Change of plasma concentration of lactate
Time Frame: 60 minutes
|
Arterial blood sampling at 0, 30 and 60 minutes after 1st dose of intrathecal study medicine.
|
60 minutes
|
|
Cumulated peroperative propofol dose
Time Frame: Up to 2 hours
|
Up to 2 hours
|
|
|
Cumulated peroperative opioid dose
Time Frame: Up to 2 hours
|
Up to 2 hours
|
|
|
Cumulated postoperative opioid dose
Time Frame: Up to 24 hours
|
Up to 24 hours
|
|
|
Time from end of operation to first opioid dose
Time Frame: Up to 24 hours
|
Up to 24 hours
|
|
|
Surgeons self reported satisfaction with anesthesia
Time Frame: Up to 2 hours
|
Numeric rating scale: 0-10
|
Up to 2 hours
|
|
Patients worst pain during surgery
Time Frame: Up to 2 hours
|
Numeric rating scale: 0-10
|
Up to 2 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Niels D Nielsen, MD, Aarhus University, Dept. of Clinical Medicine
- Study Director: Thomas F Bendtsen, MD, PhD, Aarhus University Hospital, Dept. of Anesthesiology
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HIP/FUSION#1
- 2015-003498-13 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.